Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-10-12
Based on 126 first isolates · ICU · Skin / wound infection · 2024-10-13 → 2025-10-12
Intensive care unit
Per-organism detail: ICU wound resistance view →
No single agent reaches 80 % coverage for this profile. Highest coverage without active warning:
vancomycin 54 % (45 %–62 %)
Best two-drug combination: vancomycin + meropenem covers 98 % (93 %–99 %)
Take cultures before treatment; consider a combination and discuss with infectious diseases if the patient is severely ill.
Not covered: Pseudomonas aeruginosa (16 %), Escherichia coli (13 %), Citrobacter freundii (9 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
vancomycin VAN
trend · Staphylococcus aureus Gram-positive only
54 %
50 %
n = 4
meropenem MEM
trend · Pseudomonas aeruginosa reserve
44 %
50 %
n = 4
piperacillin-tazobactam TZP
trend · Pseudomonas aeruginosa broad spectrum
41 %
25 %
n = 4
38 %
50 %
n = 4
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
38 %
25 %
n = 4
ceftriaxone CRO
trend · Escherichia coli
29 %
25 %
n = 4
27 %
25 %
n = 4
25 %
0 %
n = 4
13 %
25 %
n = 4
mecillinam MEC
not for this site
0 %
0 %
n = 4
trimethoprim TMP
not for this site
0 %
0 %
n = 4
nitrofurantoin NIT
not for this site
0 %
0 %
n = 4

Most likely organisms for this profile

Staphylococcus aureus
40 %
Pseudomonas aeruginosa
16 %
Enterococcus faecalis
13 %
Escherichia coli
13 %
Citrobacter freundii
9 %
Proteus mirabilis
6 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.